- Home
- STHO vs ALDX Comparison
STHO vs ALDX Comparison
Compare STHO & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STHO | ALDX |
|---|---|---|
| Founded | 2022 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.3M | 124.9M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | STHO | ALDX |
|---|---|---|
| Price | $9.83 | $1.48 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 17.1K | ★ 739.0K |
| Earning Date | 05-08-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.73 | ★ 40.43 |
| EPS | ★ 2.58 | N/A |
| Revenue | ★ $110,143,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.73 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.08 | $1.07 |
| 52 Week High | $9.94 | $5.93 |
Technical Indicators
Market Signals| Indicator | STHO | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 51.81 | 44.78 |
| Support Level | $8.71 | $1.47 |
| Resistance Level | $9.76 | $1.60 |
| Average True Range (ATR) | 0.28 | 0.07 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 66.31 | 48.77 |
Price Performance
Historical ComparisonAbout STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties, and land and development properties.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.